Browse studies

Find your next paid study

1 recruiting study matching your filters

SERAFA-1: A Single Arm, Open Label, Multicentre, Phase IIIb Study Of Camizestrant Plus Ribociclib in 1st Line Treatment of ER Positive, HER2-negative Advanced Breast Cancer Patients

The purpose of this study is to investigate the efficacy, safety, and tolerability of camizestrant in combination with ribociclib in patients with ER+ HER2- BC…

ER-Positive HER2-Negative Breast Cancer

Estimated

~$10 – $7,500

AstraZenecaNCT07647328